Join
Live feed
·
PRReleasevia Quantisnow
Theriva Biologics Inc. logo

Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

ByQuantisnow·Wall Street's wire, on your screen.
TOVX· Theriva Biologics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TOVX (Theriva Biologics Inc.) and more on Quantisnow.